Cell therapy weekly: FDA approves Phase I trial of cryopreserved, cord blood-derived, T-regulatory cells for COVID-19-associated ARDS

This week: Orgenesis (MD, USA) and the Edith Wolfson Medical Center (Tel Aviv, Israel) announce their collaboration over a clinical study to validate Orgenesis’ novel cell culturing system for generating tumor infiltrating lymphocytes, AgeX Therapeutics (CA, USA) and ImStem Biotechnology (CT, USA) sign a non-binding letter of intent regarding an investigational MSC product being considered for COVID-19-associated ARDS and more. The news highlights: FDA approves Phase I trial of cryopreserved, cord blood-derived T-regulatory cells for COVID-19-associated ARDS Collaboration over clinical study to validate novel cell culturing system for generating tumor infiltrating lymphocytes Companies sign non-binding letter of intent regarding investigational...